Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone
Open Access
- 1 November 2008
- journal article
- research article
- Published by Elsevier BV in Neuromuscular Disorders
- Vol. 18 (11), 857-868
- https://doi.org/10.1016/j.nmd.2008.06.386
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginoneAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Myostatin does not regulate cardiac hypertrophy or fibrosisNeuromuscular Disorders, 2007
- Age-related changes in the motricity of the inbred mice strains 129/sv and C57BL/6jBehavioural Brain Research, 2007
- New Approaches in the Therapy of Cardiomyopathy in Muscular DystrophyAnnual Review of Medicine, 2007
- Pathophysiology of Duchenne Muscular Dystrophy: Current HypothesesPediatric Neurology, 2007
- Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-β signalingCell and tissue research, 2006
- Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumoursEuropean Journal Of Cancer, 2006
- Pattern of Pax7 expression during myogenesis in the posthatch chicken establishes a model for satellite cell differentiation and renewalDevelopmental Dynamics, 2004
- Halofuginone: From veterinary use to human therapyDrug Development Research, 2000
- Functional regeneration in the hindlimb skeletal muscle of the mdx mouseJournal of Muscle Research and Cell Motility, 1988